Document Detail

Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man.
MedLine Citation:
PMID:  6368883     Owner:  NLM     Status:  MEDLINE    
Mechanisms for the hypolipidemic action of gemfibrozil were examined in seven patients with hypertriglyceridemia. In addition, seven hyperlipidemic patients were studied with and without clofibrate treatment to compare the mechanisms by which these two drugs lower plasma triglyceride levels. All patients were studied on a metabolic ward. The first month was a control period, followed by one month of either gemfibrozil or clofibrate therapy. During treatment with gemfibrozil, plasma total triglyceride levels decreased by an average of 51%, and triglyceride levels in very low-density lipoproteins (VLDLs) fell by 57%. Transport rates of VLDL triglyceride were determined by multicompartmental analysis following injection of tritiated glycerol as a precursor. Gemfibrozil decreased transport (production) of VLDL triglyceride by an average of 28% and increased the fractional catabolic rate (FCR) of VLDL triglyceride by 92%. Clofibrate reduced plasma total triglyceride values on an average of 32% and VLDL triglyceride values by 38%. In contrast to gemfibrozil, clofibrate did not change transport rates of VLDL triglyceride but increased the fractional catabolic rate of VLDL triglyceride by 35%. Gemfibrozil thus decreased production of VLDL triglyceride and enhanced its clearance, while clofibrate only increased clearance of VLDL triglyceride. On the average, plasma cholesterol levels did not fall during gemfibrozil treatment, but levels of cholesterol in high-density lipoproteins and in low-density lipoproteins increased by 31% and 11%, respectively. The drug produced a 30% increase in fecal excretion of neutral steroids and a 37% decrease in fecal excretion of bile acids. Outputs of total neutral steroids and net cholesterol balance thus remained unchanged.
Y A Kesäniemi; S M Grundy
Related Documents :
3965863 - Influence of polyunsaturated fats and fat restriction on serum lipoproteins in humans.
4037723 - Origin and fate of cholesterol in rat plasma lipoproteins in vivo. i. qualitative analy...
22268953 - The adaptive significance of mandibular symphyseal fusion in mammals.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  JAMA     Volume:  251     ISSN:  0098-7484     ISO Abbreviation:  JAMA     Publication Date:  1984 May 
Date Detail:
Created Date:  1984-05-15     Completed Date:  1984-05-15     Revised Date:  2014-09-17    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2241-6     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cholesterol / blood,  metabolism*
Cholesterol, HDL
Cholesterol, LDL
Clinical Trials as Topic
Clofibrate / therapeutic use*
Hyperlipidemias / drug therapy*,  metabolism
Hypolipidemic Agents / therapeutic use*
Lipoproteins, HDL / blood
Lipoproteins, LDL / blood
Lipoproteins, VLDL / blood
Middle Aged
Pentanoic Acids / therapeutic use*
Steroids / metabolism
Triglycerides / blood*
Valerates / therapeutic use*
Grant Support
Reg. No./Substance:
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hypolipidemic Agents; 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 0/Lipoproteins, VLDL; 0/Pentanoic Acids; 0/Steroids; 0/Triglycerides; 0/Valerates; 0/very low density lipoprotein triglyceride; 97C5T2UQ7J/Cholesterol; HPN91K7FU3/Clofibrate; Q8X02027X3/Gemfibrozil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial.
Next Document:  Treatment of sexual precocity by removal of a luteinizing hormone-releasing hormone secreting hamart...